Cancer Discovery publication applies TIMING to show increased serial killing by novel CAR NK therapy
CAR27 NK cells with CD28-based costimulation resulted in significantly better long-term cytotoxicity, polyfunctionality, and survival in animals
PUBLICATION ALERT
HOUSTON, Texas — October 21, 2024. CellChorus®, the dynamic single-cell analysis company™, announced that authors from the University of Texas MD Anderson Cancer Center, the University of Houston, the Technical University of Munich, Baylor College of Medicine, the University of Nebraska Medical Center at Omaha, and CellChorus published data in Cancer Discovery describing the design of a novel CAR27 NK therapy with CD28 costimulation for patients with CD70+ hematologic malignancies and solid cancers.
The CellChorus TIMING platform can directly measure serial killing—the ability of a natural killer (NK) cell to kill more than one target cancer cell—at the single-cell level. In the published research, the TIMING™ platform quantified the difference in serial killing between the CARs harboring varying intracellular domains. Approximately three times more NK cells were able to kill more than one target cancer cell when the best intracellular domain was used, as shown below.
The first author is Sunil Acharya, PhD, and the corresponding author is Katy Rezvani, MD, PhD, both of the MD Anderson Cancer Center. The title of the publication is "CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis" and it is available in the October 1, 2024 issue of Cancer Discovery. To read the publication and see example videos from the TIMING platform, please visit the Cancer Discovery website:
CAR27-28ζ NK cells show superior serial killing ability. Left: Kaplan-Meier curves illustrating the percentage of apoptotic (dead) target cancer cells after six hours of coculture with either the newly designed CAR NK therapy (CAR27-28ζ) or the comparison CAR NK therapy (CAR27-ζ) in nanowell grids one NK cell and two target cells (1E:2T). Right: Graph showing the total number of nanowells analyzed for CAR27-ζ and CAR27-28ζ NK cells during their coculture with target cancer cells at a 1:2 E:T ratio. The categories "0 killed," "1 killed," and "2 killed" represent the killing efficiency of each NK cell where "2 killed" signifies the ability of one NK cell to eliminate two target cancer cells, serving as a measure of the NK cells' serial killing capacity.
Source: Cancer Discov (2024) 14 (10): 1879–1900.
About CellChorus
CellChorus® is the leader in applying artificial intelligence to quantify the function and performance of cells over time to improve the development and delivery of novel therapies that improve patient care. The company applies Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) with neural network-based detection to identify how multiple types of cells move, activate, kill, proliferate, and survive at single-cell resolution. The patent-protected platform links TIMING data with other single-cell modalities to provide a comprehensive understanding of cellular function and therapeutic potential. Please visit cellchorus.com for more information.
Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com
SOURCE CellChorus Inc.